It certainly has been a wild ride for RNA interference (RNAi), a unique class of therapeutics believed to be the next wave of novel medicines. From the initial euphoria about the technology with its huge potential for the development of targeted therapeutics for cancer and other diseases, we have witnessed a reality check in recent years as serious challenges began to surface related to the problems of finding effective delivery of these constructs to their intended targets. Read More
In April, Arrowhead Research Corp. bought Alvos Therapeutics Inc. in an all-stock deal valued at about $2.1 million plus additional stock worth up to $23.5 million based on the achievement of clinical and regulatory milestones. Read More
Biotechnology companies have an insatiable appetite for cash to fuel their drug development programs. However during the past several years, apart from the industry's "blue chip" companies, the majority of biotechs have been forced into a strict diet as financing has become more difficult and costly to secure. With follow-on financings becoming challenging and costly to complete given the current state of the capital markets, publicly listed companies are turning to alternative forms of financing. One of these vehicles is at-the-market (ATM) financing. Read More
